Related Experiment Video
Updated: Sep 29, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
[High expression of p15 antisense RNA is a frequent event in acute myeloid leukemia]
Yufeng Liao1, Donghai Le, Zhankun Zhu
1Department of Laboratory Medicine, Ningbo Second Hospital, Ningbo, Zhejiang 315010, China. liaoyufengs@163.com.
Objective:
To detect the presence of p15 antisense RNA(p15AS) in acute myeloid leukemia(AML).
Methods:
p15AS and p15 mRNA in two leukemia cell lines was detected with strand-specific primer RT-qPCR. To explore the connection between p15AS and AML, 43 patients with newly diagnosed AML and 21 patients with benign diseases (Iron deficiency anemia) as controls were enrolled. The expression level of p15AS in bone marrow cells derived from the patients and the controls were determined by strand-specific primer RT-qPCR, and its relationship with clinical features was analyzed.
Results:
The two AML lines displayed high p15AS and low p15 expression. Samples derived from the AML patients showed relatively increased expression of p15AS and down-regulated p15 expression in their bone cells. In contrast, the 21 controls showed high expression of p15 but relatively low expression of the p15AS. Compared with the normal controls, the expression levels of p15 protein were significantly lower among the AML patients (P<0.01). No relationships were detected between the level of p15AS and the patient's age, gender, FAB subtype, total white blood cell count, platelet count, proliferative degree of bone marrow cell and karyotype classification (P>0.05 for all comparisons).
Conclusion:
High expression of p15 antisense RNA was frequently found among AML patients, and may play an important role in epigenetic silencing of p15.
Insights
High expression of p15 antisense RNA (p15AS) was detected in acute myeloid leukemia (AML) patients. This suggests p15AS may play a role in the epigenetic silencing of p15 in AML.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Research
Context:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- The role of non-coding RNAs in AML pathogenesis is an emerging area of research.
- p15 gene is a known tumor suppressor frequently silenced in various cancers.
Purpose:
- To investigate the expression of p15 antisense RNA (p15AS) in acute myeloid leukemia (AML).
- To determine the correlation between p15AS expression and clinical features in AML patients.
- To explore the potential role of p15AS in the epigenetic regulation of the p15 gene in AML.
Summary:
- Strand-specific RT-qPCR was employed to detect p15AS and p15 mRNA in leukemia cell lines and bone marrow samples from 43 AML patients and 21 controls.
- AML patients exhibited significantly higher p15AS expression and lower p15 expression compared to healthy controls.
- No significant association was found between p15AS levels and common clinical parameters in AML.
Impact:
- This study identifies p15AS as a frequently overexpressed transcript in AML.
- Findings suggest that p15AS may contribute to the epigenetic silencing of the p15 tumor suppressor gene in AML.
- p15AS represents a potential biomarker and therapeutic target in AML.
Related Concept Videos
Non-LTR Retrotransposons
lncRNA - Long Non-coding RNAs
Abnormal Proliferation

